Claro Advisors LLC Acquires 456 Shares of Pfizer Inc. (NYSE:PFE)

Claro Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 1.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,528 shares of the biopharmaceutical company’s stock after purchasing an additional 456 shares during the period. Claro Advisors LLC’s holdings in Pfizer were worth $1,097,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. GoalVest Advisory LLC lifted its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth $32,000. Trivant Custom Portfolio Group LLC grew its stake in Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter worth $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.9 %

NYSE PFE opened at $28.22 on Tuesday. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $159.91 billion, a PE ratio of -470.25, a P/E/G ratio of 1.10 and a beta of 0.69. The stock has a 50-day simple moving average of $27.90 and a 200 day simple moving average of $27.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.23 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.95%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Morgan Stanley raised their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, June 26th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $35.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.